To view enhanced content for this article go to http://www.medengine.com/Redeem/B1CCF06063563D18.
Poor adherence to acne treatment may lead to unnecessary treatments, increased healthcare costs, and reduced quality of life (QoL). This multicenter study evaluated the effect of supplementary patient education material (SEM) (a short video, information card, and additional information available online) on treatment adherence and satisfaction among acne patients treated with the fixed-dose combination adapalene 0.1%/benzoyl peroxide 2.5% gel (A/BPO) in primary care clinics versus (1) standard-of-care patient education (SOCPE) (package insert and oral instruction) and (2) SOCPE plus more frequent clinic visits.
Subjects with acne were randomized to receive once-daily A/BPO for 12 weeks plus (1) SEM in addition to SOCPE; (2) SOCPE only with two additional visits; or (3) SOCPE only. Other assessments included a subject appreciation questionnaire, a physician questionnaire, and safety.
Ninety-seven subjects were enrolled. At baseline, most (87.6%) had mild to moderate acne. Better adherence was observed in the A/BPO + SEM group compared with A/BPO + more visits or A/BPO alone [mean 63.1%, 48.2% (p = 0.0206), and 56.5%, respectively]. The A/BPO + SEM group had more subjects with greater than 75% adherence (45%, 30.4%, and 25%, respectively). According to the subject appreciation questionnaire, the SEM was more helpful to adhere to treatment (56.7%) versus more visits (32.3%) and A/BPO alone (15.2%), better use the product (70%, 61.3%, and 54.5%, respectively), and better manage skin irritation (53.3%, 48.4%, and 36.4%, respectively). All physicians were satisfied with the SEM and 90% would consider using it in their practice. Safety assessment showed fewer treatment-related adverse events in the A/BPO + SEM group.
Use of the SEM may increase adherence of acne patients treated with once-daily A/BPO gel in primary care, consequently improving treatment and QoL in the long term.
Nestle Skin Health-Galderma R&D.
ClinicalTrials.gov Identifier: NCT02307266.
Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18:524–6. PubMed
Andres P, Pernin C, Poncet M. Adapalene–benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants. Cutis. 2008;81:278–84. PubMed
Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene–benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84:110–6. PubMed
Heaton E, Levender MM, Feldman SR. Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions. J Dermatol Treat. 2013;24:82–8. CrossRef
Sandoval LF, Semble A, Gustafson CJ, et al. Pilot randomized-control trial to assess the effect product sampling has on adherence using adapalene/benzoyl peroxide gel in acne patients. J Drugs Dermatol. 2014;13:135–40. PubMed
National Institute for Clinical Excellence (NICE) Referral advice: a guide to appropriate referral from general to specialist services. London: NICE; 2001. http://carepathways4gp.org.uk/Acne_Care_Pathway/Referral_criteria_(NICE)_files/iGWmJf-Referraladvice.pdf. Accessed 05 Oct 2017.
Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;81:81–6. PubMed
Gollnick HP, Funke G, Kors C, et al. Efficacy of adapalene/benzoyl peroxide combination in moderate inflammatory acne and its impact on patient adherence. J Dtsch Dermatol Ges. 2015;13:557–65. PubMed
- Use of Supplementary Patient Education Material Increases Treatment Adherence and Satisfaction Among Acne Patients Receiving Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in Primary Care Clinics: A Multicenter, Randomized, Controlled Clinical Study
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II